Incidence of adverse and serious adverse events
Adverse event type | Infliximab (n = 13) | Etanercept continue therapy | Escape | |||
---|---|---|---|---|---|---|
Week 0–15 | Week 16–35 | Week 0–35 | Week 0–15(n = 14) | Week 0–35(n = 5) | Week 16–35(n = 6) | |
AE, adverse event; SAE, serious adverse event. | ||||||
*AEs were reported in more than one patient. | ||||||
Serious (SAE) | n (% of patients) | n (% of patients) | ||||
Patients with ⩾1 SAE | 0 (0) | 1 (7.7) | 1 (7.7) | 2 (14.3) | 1 (20.0) | 0 (0) |
Gastrointestinal disorders | 0 (0) | 0 (0) | 0 (0) | 1 (7.1) | 1 (20.0) | 0 (0) |
Cardiac disorders | 0 (0) | 0 (0) | 0 (0) | 1 (7.1) | 0 (0) | 0 (0) |
Musculoskeletal and connective tissue disorders | 0 (0) | 1 (7.7) | 1 (7.7) | 0 (0) | 0 (0) | 0 (0) |
Nervous system disorders | 0 (0) | 0 (0) | 0 (0) | 1(7.1) | 0 (0) | 0 (0) |
Respiratory disorders | 0 (0) | 0 (0) | 0 (0) | 1 (7.1) | 0 (0) | 0 (0) |
Adverse (AE)* | ||||||
Patients with ⩾1 AE | 7 (53.8) | 4 (30.8) | 11 (84.6) | 7 (50.0) | 2 (40.0) | 2 (33.3) |
Gastrointestinal disorders | 0 (0) | 0 (0) | 0 (0) | 3 (21.4) | 1 (20) | 0 (0) |
Musculoskeletal and connective tissue disorders | 2 (15.4) | 2 (15.4) | 4 (30.8) | 1 (7.1) | 0 (0) | 2 (33.3) |
Nervous system disorders | 1 (7.7) | 0 (0) | 1 (7.7) | 1 (7.1) | 0 (0) | 1 (16.7) |
Respiratory disorders | 1 (7.7) | 0 (0) | 1 (7.7) | 4 (28.6) | 0 (0) | 0 (0) |
Skin and subcutaneous disorders | 3 (23.1) | 2 (15.4) | 5 (38.5) | 1 (7.1) | 0 (0) | 0 (0) |
General disorders and site reactions | 0 (0) | 0 (0) | 0 (0) | 1 (7.1) | 1 (20.0) | 0 (0) |